Recently, a Chinese research team successfully treated patients with autoimmune hemolytic anemia (AIHA) who had failed multiple lines of drug therapy using their independently developed autologous CD19 CAR T cells, providing a new salvage treatment option for patients who have failed conventional drug therapy.
On January 15th, the research findings of the team led by Shi Jun and Xiong Haiqing from the Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology) were published online in the *New England Journal of Medicine*, marking a new breakthrough in innovative cell and gene therapy in my country's regenerative medicine field.
It is understood that AIHA is an autoimmune hematologic disorder caused by autoantibodies attacking red blood cells, leading to accelerated red blood cell destruction and anemia. It has a high incidence and prevalence, with about half of patients progressing to a relapsed or refractory state. It can cause serious infections, sepsis, vascular embolism, etc., with a disability and mortality rate as high as 20%.
